| ATOGEPANT |
Aquipta® |
ALLERGAN AUSTRALIA PTY LIMITED |
Prophylaxis of migraine |
Jul 2023 |
Not Recommended |
| DAPRODUSTAT |
Jesduvroq® |
GLAXOSMITHKLINE AUSTRALIA PTY LTD |
Anaemia associated with chronic kidney disease |
Jul 2023 |
Not Applicable |
| TAFAMIDIS |
Vyndamax® |
PFIZER AUSTRALIA PTY LTD |
Transthyretin amyloid cardiomyopathy |
Jul 2023 |
Recommended |
| ACALABRUTINIB |
Calquence® |
AstraZeneca Pty Ltd |
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) |
Jul 2023 |
Recommended |
| CALCIPOTRIOL WITH BETAMETHASONE |
Enstilar® |
LEO Pharma Pty Ltd |
Chronic stable plaque type psoriasis vulgaris |
Jul 2023 |
Not Recommended |
| RAVULIZUMAB |
Ultomiris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Paroxysmal nocturnal haemoglobinuria (PNH) |
Jul 2023 |
Recommended |
| POMALIDOMIDE |
PomolideTM |
JUNO PHARMACEUTICALS PTY LTD |
Relapsed/refractory multiple myeloma |
Jul 2023 |
Recommended |
| SOMAPACITAN |
Sogroya® |
NOVO NORDISK PHARMACEUTICALS PTY. LIMITED |
Paediatric growth hormone deficiency (GHD) |
Jul 2023 |
Recommended |
| TRIENTINE |
Trientine Dr.Reddy's |
Dr Reddy's Laboratories (Australia) Pty Ltd |
Wilson disease |
Jul 2023 |
Recommended |
| FOSLEVODOPA WITH FOSCARBIDOPA |
Vyalev® |
ABBVIE PTY LTD |
Advanced Parkinson's Disease |
Jul 2023 |
Not Applicable |
| MIRIKIZUMAB |
Omvoh® |
ELI LILLY AUSTRALIA PTY LTD |
Moderate to severe ulcerative colitis (MUSC) |
Jul 2023 |
Recommended |
| LUMACAFTOR AND IVACAFTOR |
Orkambi® |
VERTEX PHARMACEUTICALS (AUSTRALIA) PTY. LTD. |
Cystic fibrosis |
Jul 2023 |
Recommended |
| ONASEMNOGENE ABEPARVOVEC |
Zolgensma® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Presymptomatic treatment of spinal muscular atrophy (SMA) |
Jul 2023 |
Recommended |
| ABIRATERONE AND METHYLPREDNISOLONE |
Yonsa® Mpred |
SUN PHARMA ANZ PTY LTD |
Metastatic hormone sensitive prostate cancer |
Jul 2023 |
Recommended |
| AVACOPAN |
Tavneos® |
VIFOR PHARMA PTY LIMITED |
Severe active granulomatosis with polyangiitis (GPA) and severe active microscopic
polyangiitis (MPA) |
Jul 2023 |
Not Recommended |
| DAUNORUBICIN WITH CYTARABINE |
Vyxeos® |
Jazz Pharmaceuticals ANZ Pty Ltd |
Acute myeloid leukaemia |
Jul 2023 |
Not Recommended |
| SECUKINUMAB |
Cosentyx® |
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED |
Hidradenitis Suppurativa (HS) |
Jul 2023 |
Not Recommended |
| MOLNUPIRAVIR |
Lagevrio® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Mild to moderate COVID-19 |
Jul 2023 |
Advice Provided |
| IXEKIZUMAB |
Taltz® |
ELI LILLY AUSTRALIA PTY LTD |
Non-radiographic axial spondyloarthritis (nr-AxSpA) |
Jul 2023 |
Not Recommended |
| TIRZEPATIDE |
Mounjaro® |
ELI LILLY AUSTRALIA PTY LTD |
Type 2 Diabetes Mellitus (T2D) |
Jul 2023 |
Not Recommended |
| DUPILUMAB |
Dupixent® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Chronic severe atopic dermatitis |
Jul 2023 |
Advice Provided |
| SELPERCATINIB |
Retevmo® |
ELI LILLY AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Jul 2023 |
Not Recommended |
| ESKETAMINE |
Spravato® |
JANSSEN-CILAG PTY LTD |
Treatment resistant depression |
Jul 2023 |
Not Recommended |
| NUSINERSEN |
Spinraza® |
BIOGEN AUSTRALIA PTY LTD |
Pre-symptomatic spinal muscular atrophy (SMA) |
Jul 2023 |
Recommended |
| PATISIRAN |
Onpattro® |
ALNYLAM AUSTRALIA PTY LTD |
Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) |
Jul 2023 |
Not Recommended |
| MOBOCERTINIB |
Exkivity® |
TAKEDA PHARMACEUTICALS AUSTRALIA PTY. LTD. |
Locally advanced or metastatic non-small cell lung cancer (NSCLC) |
Jul 2023 |
Recommended |
| DAPAGLIFLOZIN |
Forxiga® |
ASTRAZENECA PTY LTD |
Chronic heart failure |
Jul 2023 |
Recommended |
| SACITUZUMAB GOVITECAN |
Trodelvy® |
GILEAD SCIENCES PTY LIMITED |
Hormone receptor positive (HR+) human epidermal growth factor receptor-2 negative
(HER2-) advanced or metastatic breast cancer |
Jul 2023 |
Not Recommended |
| ADALIMUMAB |
|
CIPLA AUSTRALIA PTY LTD |
Severe Crohn disease; moderate to severe ulcerative colitis; Severe active juvenile
idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active
rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic
plaque psoriasis; Moderate to severe hidradenitis suppurativa |
Jul 2023 |
Recommended |
| MAVACAMTEN |
Camzyos® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Hypertrophic cardiomyopathy |
Jul 2023 |
Not Recommended |
| ENOXAPARIN |
ExaraneTM Exarane ForteTM |
JUNO PHARMACEUTICALS PTY LTD |
Thrombo-embolic disorders |
Jul 2023 |
Recommended |
| CABOTEGRAVIR |
Apretude® |
ViiV HEALTHCARE PTY LTD |
Pre-exposure prophylaxis of HIV infection |
Jul 2023 |
Deferred |
| SONIDEGIB |
Odomzo® |
SUN PHARMA ANZ PTY LTD |
Metastatic or locally advanced basal cell carcinoma (BCC) |
Jul 2023 |
Advice Provided |
| OLIPUDASE ALFA |
Xenpozyme® |
SANOFI-AVENTIS AUSTRALIA PTY LTD |
Acid sphingomyelinase deficiency (ASMD) |
Jul 2023 |
Not Recommended |
| RIMEGEPANT |
Nurtec ODT® |
PFIZER AUSTRALIA PTY LTD |
Acute migraine attacks |
Jul 2023 |
Not Recommended |
| TAGRAXOFUSP |
Elzonris® |
A.MENARINI AUSTRALIA PTY LIMITED |
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) |
Jul 2023 |
Not Recommended |
| USTEKINUMAB |
Stelara® |
JANSSEN-CILAG PTY LTD |
Fistulising Crohn disease |
Jul 2023 |
Recommended |
| BUDESONIDE |
Jorveza® |
DR FALK PHARMA AUSTRALIA PTY LTD |
Eosinophilic oesophagitis (EoE) |
Jul 2023 |
Recommended |
| RELATLIMAB AND NIVOLUMAB |
Opdualag® |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Melanoma |
Jul 2023 |
Recommended |
| OLAPARIB |
Lynparza® |
ASTRAZENECA PTY LTD |
Ovarian cancer |
Jul 2023 |
Recommended |
| NIVOLUMAB |
Opdivo |
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD |
Non-small cell lung cancer (NSCLC) |
Jul 2023 |
Recommended |
| DURVALUMAB |
Imfinzi® |
ASTRAZENECA PTY LTD |
Biliary tract cancer |
Jul 2023 |
Recommended |
| RAVULIZUMAB |
Ultomiris® |
Alexion Pharmaceuticals Australasia Pty Ltd |
Atypical haemolytic uraemic syndrome (aHUS) |
Jul 2023 |
Recommended |
| UPADACITINIB |
Rinvoq® |
ABBVIE PTY LTD |
Crohn disease (CD) |
Jul 2023 |
Recommended |
| TRASTUZUMAB DERUXTECAN |
Enhertu® |
ASTRAZENECA PTY LTD |
|
Jul 2023 |
Recommended |
| NIRAPARIB |
Zejula® |
GlaxoSmithKline Australia Pty Ltd |
Epithelial ovarian, fallopian tube, or primary peritoneal cancer |
Jul 2023 |
Recommended |
| PEMBROLIZUMAB |
Keytruda® |
MERCK SHARP & DOHME (AUSTRALIA) PTY LTD |
Breast cancer |
Jul 2023 |
Recommended |
| NIVOLUMAB |
Opdivo® |
Bristol-Myers Squibb Australia Pty Ltd |
Advanced or metastatic oesophageal squamous cell carcinoma |
Jul 2023 |
Recommended |